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iron storage protein, which we suspect is an important
defense against oxidative stress in neurons and elsewhere.
The 242-amino acid FtMt precursor protein is cleaved to
mature protein (of molecular weight about 22-kDa) in the
mitochondrial matrix. Compared with the ubiquitously
expressed traditional ferritin (H-ferritin and L-ferritin), FtMt
has been found in fewer locations including the testis, heart
and brain. Previous studies have reported that the expres-
sion of FtMt in mouse and human brain is predominantly
localized to neurons and partly to glial cells, and FtMt exerts
protective eﬀects on neurons by maintaining normal func-
tion and regulates apoptosis in Alzheimer’s disease and
Parkinson’s disease. To ﬁnd out the function of FtMt in neu-
rodegenerative disease, we had a novel antibody made against
human FtMt and characterized it via Western blot analysis,
immunoabsorption testing, and double immunoﬂuorescence
histochemistry. Then we used this new FtMt antibody to
map the distribution of FtMt in the monkey brainstem. We
demonstrated widespread distribution of FtMt immunoreactivity
throughout the monkey brainstem, with variable staining
intensity. FtMt immunoreactivity was observed in the
extrapyramidal system, sensory trigeminal nerve nuclei,
some motor nuclei including ambiguous nucleus, dorsal
motor nucleus of the vagus and hypoglossal nucleus, and
some dorsal column nuclei such as the gracile nucleus and
cuneate nucleus. In addition, double immunohistochemical
stainings conﬁrmed that FtMt immunoreactivity was
co-localized with catecholaminergic neurons in the locus
coeruleus (63.64%), substantia nigra pars compacta
(69.18%), and ventral tegmental area (56.89%). The distributionhttp://dx.doi.org/10.1016/j.neuroscience.2016.04.035
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92of FtMt which we found in the brainstem implies possible
involvement of FtMt in several physiological mechanisms,
especially in the catecholaminergic neurons, and the
possibility of signiﬁcant involvement in neurodegenerative
disease.  2016 The Author(s). Published by Elsevier Ltd
on behalf of IBRO. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
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INTRODUCTION
Mitochondrial ferritin (FtMt), a recently-identiﬁed iron
storage protein, is preferentially located in mitochondria
(Levi et al., 2001). FtMt is expressed as a precursor
protein (242-amino-acid long, molecular weight
around 30 kDa). It has 79% homology with H-chain
ferritin (FTH) and ferroxidase but lacks functional
iron-responsive elements (IREs). In the mitochondrial
matrix, this precursor protein is cleaved to an approxi-
mately 22-kDa mature FtMt protein, functionally and
structurally comparable to the cytosolic ferritins (Corsi
et al., 2002; Drysdale et al., 2002; Levi and Arosio,
2004). FtMt assembles into 24-mer homopolymer shells
which can act as ferroxidase and bind iron to the
mitochondrial matrix. These characteristics make it highly
likely that FtMt may protect against iron toxicity, at least
within the mitochondria (Levi et al., 2001; Corsi et al.,
2002; Levi and Arosio, 2004; Bou-Abdallah et al., 2005).
This would be consistent with our previous report that
FtMt protected neuroblastoma cells from oxidative stress
(Wang et al., 2011).
Iron, which is important in electron-transfer reactions,
is an essential transition metal in many physiological
functions. Various processes rely on reversible redox
cycling between ferric and ferrous ions (Aisen et al.,
2001; Dlouhy and Outten, 2013). Normally, plenty of iron
is stored in the brain, as it is necessary for generating
ATP in brain mitochondria. However, considerable evi-
dence indicates that iron tends to accumulate in the brain
at older ages (Connor et al., 1990; Zecca et al., 2004;
Zucca et al., 2015), and excess iron is dangerous for
cells, since it will lead to levels of toxic reactive oxygen
species (ROS) (Connor et al., 1992; Welch et al., 2002).
In fact, one hallmark of age-related diseases is excess
free iron when storage in ferritin fails; ferritin is probably
the oldest known and most widespread moleculeons.org/licenses/by-nc-nd/4.0/).
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Altamura and Muckenthaler, 2009). In cells, overloaded
iron is stored primarily in the cytoplasm, but is metaboli-
cally active mostly in the mitochondria, which are the main
source of cellular energy and intracellular ROS. Thus,
mitochondrial iron homeostasis should be tightly regu-
lated to limit oxidative damage (Levi et al., 2001; Welch
et al., 2002; Huang et al., 2011). Exactly how iron is con-
trolled in mitochondria remains unclear, but FtMt’s ability
to hold iron seems likely to be signiﬁcant.
FtMt tends to be found in metabolically highly activity
tissue such as the testes, liver, spleen, and brain, and it
is believed to be important in these tissues (Drysdale
et al., 2002; Levi and Arosio, 2004). In the brain, accumu-
lating evidence indicates involvement of FtMt in some
neurodegenerative diseases, notably Alzheimer’s disease
(AD) and Parkinson’s disease (PD), as well as in restless
legs syndrome (RLS) (Nie et al., 2005; Snyder et al.,
2009; Wang et al., 2011; Yang et al., 2013). FtMt also
seems to act as a neuroprotective protein to maintain nor-
mal neuronal function and control apoptosis (Shi et al.,
2010; Wu et al., 2013). Despite that, little has been pub-
lished about FtMt distribution in the brain. Snyder et al.
reported that FtMt-immunoreactivity was detected in neu-
rons and oligodendrocytes in the mouse brain. We also
reported that FtMt mRNA was expressed mainly by neu-
rons in the human cerebral cortex (Snyder et al., 2010;
Wang et al., 2011). However, neither of those studies
gave detailed information on FtMt distribution in the brain.
It is important to clarify the distribution patterns of FtMt
in the brainstem, due to many reports suggesting that
neurodegenerative diseases are closely associated with
certain brainstem nucleus. In this study, we
characterized a new polyclonal antibody made against
human and monkey FtMt by Western blot analysis,
immunoabsorption testing, and double
immunoﬂuorescence histochemistry. Our results proved
that it speciﬁcally recognizes FtMt, and has no cross
reaction with FTH. Using this antibody, we mapped the
presence of FtMt in the cynomolgus monkey (Macaca
fascicularis) brainstem. This study also revealed the
localization of FtMt in catecholaminergic neurons.EXPERIMENTAL PROCEDURES
Animals
The protocols of animals for this study were approved by
the Institutional Animal Care and Use Committee of Shiga
University of Medical Science. All the monkeys lived in
normal housing condition (according to the care and
feeding regulations of Animal Experiment Center of
Shiga University of Medical Science). For Western blot
analysis, the brainstem sample was obtained from two
euthanized female cynomolgus monkeys (3 years
10 months, 2.67 kg; 12 years 2 months, 5.52 kg). For
immunohistochemistry, brains were removed from four
female cynomolgus monkeys (age: 5–11 years; weight:
3.38–4.68 kg) following use for other non-pathological
study by other researchers. All eﬀorts were made to
avoid animal suﬀering and to minimize the number of
animals used.Production and characterization of an antibody
against human FtMt
We choose a synthetic peptide with an added N-terminal
Cys residue (CTLGNENKQN: Accession number
BC034419 on GenBank), which corresponds to amino
acid residues 234–242 of human FtMt, as an
immunogen. Then we requested that the Medical &
Biological Laboratory Co. Ltd. (Ina, Nagano, Japan)
produce antibodies against human FtMt. Antisera were
raised in rabbits via immunization with this immunogen
conjugated to keyhole limpet hemocyanin. Two rabbits
were immunized with this antigen. After each booster
immunization, the antisera were collected, and the best
one was puriﬁed by aﬃnity chromatography. Antibody
speciﬁcity was tested by Western blot analysis,
immunoabsorption, and ﬂuorescence microscopy as
described below.Western blot analysis
FtMt antibody speciﬁcity was checked by Western blot.
Brainstem tissue was homogenized in a glass
homogenizer with RIPA buﬀer [20 mM HEPES,
150 mM NaCl, 2 mM EDTA, 1% Nonidet P-40, 1%
deoxycholic acid, and 0.1% sodium dodecyl sulfate
(SDS) at pH 7.4] containing protease inhibitors
[AEBSF: Aprotinin, Bestatin, E64, EDTA and Leupeptin
(Sigma P2714), 1 mL/1 mg of USP pancreatin; Sigma,
St. Louis, MO, USA], as described previously (Bellier
and Kimura, 2007) with slight modiﬁcations. Mitochon-
dria were isolated with Mitochondria Isolation Kit for
Tissue (Thermo Fisher Scientiﬁc, Waltham, MA, USA)
according to manufacturer’s instructions. Protein concen-
trations were assayed using a protein dye assay reagent
(Bio-Rad Laboratories, Hercules, CA, USA) and an Inﬁ-
nite M200 reader (Tecan, Ma¨nnedorf, Switzerland).
Crude protein (approximately 5 lg), prestained precision
protein standards (Bio-Rad Laboratories), and Protein
Ladders Standards (Bio-Rad, California, USA) or Protein
Ladder One Triple-color (Nacalai Tesque, Kyoto, Japan)
were electrophoresed on a 15% SDS–polyacrylamide
gel (Wako Pure Chemical Industries, Osaka, Japan)
under reducing conditions and then transferred to a
polyvinylidene diﬂuoride membrane (Immobilon-P, Merck
Millipore, Billerica, MA, USA). Membranes were
incubated for 1 h at room temperature with 20% Blocking
reagent-N102 (NOF Corp., Tokyo, Japan) in 25 mM TBS
containing 0.1% Tween-20 (TBST; pH 7.4) to block
non-speciﬁc protein binding sites, followed by an 8 h
incubation with the polyclonal FtMt antibody (0.128 lg/mL),
cytochrome c oxidase subunit IV (COX4) (1:1000; Milli-
pore) or FTH (1:5000; Abcam, Tokyo, Japan) at 4 C.
After three 10-min washes with TBST, the membranes
were reacted with a peroxidase-labeled anti-rabbit IgG
(1:50,000; Jackson ImmunoResearch Laboratories,
West Grove, PA, USA) for 1 h at room temperature.
Peroxidase labeling was detected by chemilumines-
cence using the Super Signal West Pico Chemilumines-
cent Substrate (Thermo Fisher Scientiﬁc, Waltham, MA,
USA).
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primary antibody. We also performed an
immunoabsorption test as another control. For this test,
the puriﬁed antibody was pre-incubated with FtMt
peptide (0.187 lg/mL) or human FTH full-length
recombinant protein (Alpha Diagnostic International, San
Antonio, USA) (0.357 lg/mL) at 4 C for 24 h, and the
membranes were incubated as described above.Tissue preparation
Tissue preparation was performed essentially according
to previous reports (Abdelalim and Tooyama, 2011;
Bisem et al., 2012). Brain stem samples were removed
from four M. fascicularis, as mentioned above. Brains
were collected at separate times and processed sepa-
rately. All were ﬁxed immediately with 4% paraformalde-
hyde in 0.1 M phosphate buﬀer (pH 7.4) for 3 days at
4 C. Next, the samples were immersed for 4 days in
15% sucrose in 0.1 M PB with 0.1% sodium azide; the
sucrose solution was daily changed. The brains were then
stored in 15% sucrose solution at 4 C until sectioning.
Samples were cryosectioned at 20 C into 20-lm
serial coronal sections that were ﬂoated in 0.1 M
phosphate-buﬀered saline containing 0.3% Triton X-100
(PBST) at pH 7.4, and then maintained in PBST with
sodium azide at 4 C.Immunohistochemistry
Immunohistochemical staining for FtMt was performed as
previously described (Abdelalim and Tooyama, 2011). In
brief, sections were steeped in 0.1 M PBST (pH 7.4) for
3 days at 4 C before staining. Sections were incubated
for 40 min in PBST containing 0.1% sodium azide and
0.3% H2O2 at room temperature to inhibit endogenous
peroxidase. After three 10-min washes in PBST, sections
were incubated for 1 h with PBST containing 2% BSA.
Next, the sections were incubated with puriﬁed FtMt
antibody (0.128 lg/mL) for 3 days at 4 C. After washing,
the sections were incubated with biotinylated anti-rabbit
IgG (1:3000; Vector Laboratories, Burlingame, CA,
USA) for 1 h at room temperature. Finally, sections were
incubated with ABC complex (1:3,000; ABC Elite; Vector
Laboratories) for 1 h at room temperature, then the sec-
tions were developed in 0.02% 3,3-diamine-benzidine
tetrahydrochloride with 0.3% nickel ammonium sulfate in
50 mM Tris–HCl (pH 7.6) containing 0.005% hydrogen
peroxide. PBST was used to wash the sections between
steps. For the immunoabsorption test, the FtMt antibody
was pre-incubated with FtMt peptide (0.187 lg/mL) for
24 h at 4 C, and the sections were stained as described
above.Mapping
Mapping of FtMt distribution in the monkey midbrain,
pons, and medulla oblongata was performed using
camera lucida as described previously (Abdelalim et al.,
2007; Bisem et al., 2012).Immunoﬂuorescence staining
Tests were done in some midbrain sections to compare
localization of FtMt and tyrosine hydroxylase
(TH)-positive neurons, using double labeling for FtMt
and TH, with ﬂuorescently labeled secondary. To verify
FtMt localization in the mitochondria, similar double
labeling was done using FtMt and mitochondrial marker
COX4 (a terminal enzyme of the mitochondrial electron
transport chain) with ﬂuorescently labeled secondary
antibodies. Some sections were incubated with a
mixture of FtMt polyclonal antibody (0.128 lg/mL) and a
monoclonal antibody against TH (1:5000; Millipore) or
COX4 (1:500; Millipore) at 4 C overnight. After
washing, sections were incubated in a mixture of Alexa
Fluor 488-labeled anti-rabbit and Alexa Fluor
647-labeled anti-mouse secondary antibodies (1:500
dilutions; Molecular Probes Inc., Eugene, OR, USA) for
2 h at room temperature. After washing three times in
phosphate-buﬀered saline (PBS), the sections were
mounted on coated glass slides. Fluorescence was
detected using a scanning laser confocal microscope
(TE2000-E, Nikon, Tokyo, Japan). Single optical
slice images were taken using 10, 20, or 40
Plan-Neoﬂuor dry objective lenses.
Micrographs
Digital images taken with a Nikon-D90 digital camera
(Tokyo, Japan) on an Olympus Microscope BX50
(Tokyo, Japan) were adjusted only for the brightness
and contrast using Adobe Photoshop, with no further
image manipulation. To add labels, an open source
vector graphics editor named Inkscape was used.
RESULTS
Characterization of the FtMt antibody
The FtMt antibody was characterized by Western blot
analysis of proteins, isolated mitochondria and cytosolic
fractions extracted from the monkey midbrain, as well
as an immunoabsorption test. In the Western blot
analysis, the FtMt antibody detected a single band
around 22 kDa, consistent with the known molecular
weight of FtMt (arrow in Fig. 1A). Without the primary
antibody, no such bands were observed; nor were they
seen after the antibody was pre-absorbed with FtMt
peptide (Fig. 1A). The antibody detected FtMt in
mitochondria fraction (arrow in Fig. 1B), but not in
cytosolic fraction (Fig. 1B).
In addition, this antibody did not recognize FTH, as
bands representing FtMt and FTH (Fig. 1C) were
observed at diﬀerent molecular weights. When the
antibody was pre-absorbed with human FTH full-length
recombinant protein, the signal did not reduce compared
to the non-absorbed FtMt antibody (Fig. 1D). However,
no bands were observed when FTH antibody was pre-
incubated with this FTH recombinant protein (Fig. 1E).
In tissues, this antibody stained neuronal cell bodies in
speciﬁc brain regions (Fig. 1F). The staining was
abolished when FtMt antibody pre-absorbed with FtMt
peptide was used (Fig. 1G).
Fig. 1. FtMt antibody characterization. (A) Western blot analysis of crude protein extract from a monkey brainstem, using our rabbit polyclonal anti-
FtMt antibody (FtMt+). Adjacent lanes were loaded with equivalent amounts of protein. The antibody recognized a single band at approximately
22 kDa (arrow). No bands were observed without primary antibody (FtMt) or when antibody pre-absorbed with FtMt peptide was used (Pre-ab). (B)
The antibody recognized FtMt in mitochondrial fraction (arrow in mito), but not in cytosolic fraction of monkey brainstem (cyto). (C) The antibody did
not cross-react with monkey H-ferritin. FtMt and FTH bands were observed at diﬀerent molecular weights. (D) The FtMt band signal was
undiminished when antibody was pre-absorbed with human FTH full-length recombinant protein. (E) As a positive control, FTH signal was abolished
following pre-incubation of the antibody with the FTH recombinant protein. (F) Immunostaining of FtMt in the oculomotor nucleus of the monkey
midbrain, using our rabbit polyclonal anti-FtMt antibody. (G) No positive structures were detected when the antibody was pre-absorbed with FtMt
peptide. Scale bars = 100 lm (C, D).
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brainstem
Western blotting of protein from mitochondria and
cytosolic fractions revealed signal for COX4 only in total
crude protein and mitochondria fraction extracted from
monkey brainstem, but no band in the cytosolic fraction
(Fig. 2A), indicating successful isolation of mitochondrial
and cytoplasmic fractions from monkey brainstem.
In the oculomotor nucleus (III), FtMt immunoreactivity
was detected mainly in the cytoplasm of neurons.
Confocal microscopic analysis revealed punctate FtMt
positivity in the cytoplasm (Fig. 2B). Double
immunoﬂuorescent staining with the mitochondrial
marker COX4 conﬁrmed that FtMt was colocalized to
COX4-positive mitochondria (Fig. 2D).Distribution of FtMt in the monkey brainstem
Widespread distribution of FtMt immunoreactivity was
observed throughout the cynomolgus monkey brainstem
in some neuronal structures, and some vessels were
also weakly stained. FtMt immunoreactivity distribution
seemed the same in all four monkey brainstems which
we tested. Preferential FtMt staining was observed in
neuronal cells, judging by simple morphological criteria
(the size, shape and location of cells). The apparent
staining of FtMt-positive neurons varied in intensity and
density between regions, as summarized in Table 1.
Fig. 3 represents the FtMt immunoreactivity distribution
in the midbrain (Fig. 3A, B), pons (Fig. 3C–E), and
medulla oblongata (Fig. 3E–G), drawn using a camera
lucida. As shown in Fig. 3, the highest density of
Fig. 2. FtMt localized in mitochondria. (A) Western-blot analysis
conﬁrmed isolation of the mitochondrial fraction and cytosolic fraction
from monkey brainstem. COX4 (arrows) was observed in total crude
protein (total) and mitochondrial fraction (mito), but not in the cytosolic
fraction (cyto). Confocal microscopic images of double immunoﬂuo-
rescent histochemistry for FtMt (B), Cox4 (B), and merged staining
(C). Scale bars = 5 lm.
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medulla oblongata, followed by the midbrain. These
include catecholaminergic neurons (VTA, SNc, LC),
sensory systems (MeV, Sp5, GR, LCU, and MCU), the
extrapyramidal system (SC, IC, RN, PN, LR, LVe, MVe,
DR, and MR) and some motor nuclei (AMB, DMNV, andTable 1. Summary and abbreviations of brain regions where FtMt-positive sta
Region and Abbreviations Density Intensity
Midbrain
Central gray (CG) 1 +
Substantia nigra pars compacta (SNc) 3 ++
Substantia nigra pars reticular (SNr) – –
Red nucleus (RN) 1 ++
Ventral tegmental area (VTA) 2 +
Oculomotor nucleus (III) 3 ++
Interpeduncular nucleus (IP) – –
Central tegmental ﬁeld (CTF) 3 +
Edinger–Westphal nucleus (EW) ++ ++
Dorsal raphe nucleus (DR) 2 ++
Medial geniculate body (MGB) 3 ++
Superior colliculus (SC) 3 +
Inferior colliculus (IC) 3 +
Trochlear nucleus (IV) 2 ++
Pons
Pedunculopontine tegmental nucleus (PPT) 2 ++
Pontine reticular nucleus (RTP) 2 ++
Pontine nuclei (PN) 2 ++
Locus coeruleus (LC) 3 +
Mesencephalic trigeminal nucleus (Me5) 1 +++
Motor trigeminal nucleus (Mo5) 2 ++
Median raphe nucleus (MR) 2 ++
Ventral raphe nucleus (VR) 2 +
Nucleus of trapezoid body (NTB) 1 +
Density of staining: 1, low; 2, intermediate; 3, high.
Intensity of staining: +, weak; ++, moderate; +++, strong.XII). The widespread distribution of FtMt suggests that
FtMt is involved in various brain functions.
Distribution of FtMt in the midbrain
In the midbrain, FtMt immunoreactivity was seen in the
cytoplasm and neuronal processes (arrowheads in
Fig. 4) in the SNc, VTA, tectum, EW, III, RN, MGB, IV,
and DR. FtMt immunoreactivity of varying intensity was
observed in neurons in the SNc (Fig. 4A). FtMt
immunoreactivity was primarily observed in pigmented
cells (star), with positive staining in only a few non-
pigmented cells (hollow star). Some FtMt
immunoreactivity was observed in nuclei (hollow arrows)
and ﬁbers (hollow arrowheads). FtMt-immunoreactive
neurons extended to the VTA (Fig. 4A).
Weakly stained FtMt-immunoreactive neurons were
seen in the superior and inferior colliculus (Fig. 4B).
Some ependymal cells showed intense FtMt staining
(Fig. 4B). FtMt-immunoreactive neurons with moderately
intense staining were observed in the EW and III
(Fig. 4C). Mild FtMt immunoreactivity was seen
in the RN (Fig. 4C). Many closely-packed olivary
FtMt-immunoreactive neurons were observed in the
MGB (Fig. 4D). Some vessels were also weakly
stained (arrows in Fig. 4D). In the caudal level,
FtMt-immunoreactive neurons were found in the ventral
side of the DR (Fig. 4E, F) and IV (Fig. 4E, G).
Distribution of FtMt in the pons
FtMt immunoreaction was observed in neurons of several
regions (arrowheads in Fig. 5), including LVe, VI, MR, VR,inings
Region and Abbreviations Density Intensity
Abducens nucleus (VI) 2 ++
Lateral vestibular nucleus (LVe) 3 ++
Parabrachial nucleus (PB) — —
Medulla oblongata
Medial vestibular nucleus (MVe) 3 ++
Gracilis nucleus (GR) 2 +
Lateral cuneate nucleus (LCU) 3 +++
Medial cuneate nucleus (MCU) 3 +++
Raphe obscurus nucleus (RO) 3 +
Medial longitudinal fasciculus (MLF) 3 ++
Spinal trigeminal nucleus (Sp5) 3 ++
Ambiguus nucleus (AMB) 3 +++
Supraspinal nucleus (SSp) 2 +++
Lateral reticular nucleus (LR) 2 ++
Inferior olivary nucleus (IO) 3 ++
Nucleus of the solitary tract (SOL) 3 +
Dorsal motor nucleus of vagus (DMNV) 3 +++
Hypoglossal nucleus (XII) 3 +++
Cerebellum
Deep cerebellar nuclei (CBN) 3 ++
Molecular layer (M layer) 3 ++
Purkinje cell layer (P cells) 1 +++
Granular cell layer (G cells) 3 ++
Fig. 3. Distribution of FtMt immunoreactivity in the brainstems of cynomolgus monkeys, drawn from representative sections using a camera lucida.
Directional reference orientation is shown at the bottom, indicating the orientation: S: Superior, I: Inferior, R: Right, L: Left, F: Frontal, and
C:Caudal.
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Fig. 4. FtMt immunoreactivity in the midbrains of cynomolgus monkeys. (A–G) FtMt-immunoreactivity in speciﬁc regions of the midbrain.
Arrowheads indicate immunoreactivity in the cytoplasm and neuronal processes. Higher magniﬁcation images of FtMt immunoreactivity are shown
in boxed areas (A–E). (A) The substantia nigra (SN) and ventral tegmental area (VTA). A Star indicate pigmented cells, a hollow star indicate
non-pigmented cells, hollow arrows indicate nuclei, and hollow arrowheads indicate ﬁbers. (B) Superior colliculus (SC) and ependymal cells. (C)
Edinger–Westphal (EW), oculomotor (III), and red nuclei (RN). (D) Medial geniculate body (MGB) and blood vessels (BV) (arrows). (E) Dorsal raphe
(DR) and trochlear (IV) nucleus. (F, G) High-magniﬁcation images of FtMt immunoreactivity in the IV and DR. Scale bars = 500 lm (A, B, C, E),
200 lm (D), 50 lm (F, G).
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multipolar immunoreactive neurons were seen in the
LVe (Fig. 5A). Strongly stained FtMt-immunoreactive
neurons were observed in the VI under the fourth
ventricle (Fig. 5A). Neurons in the MR and RTP
exhibited intense FtMt staining (Fig. 5B). In the VR,
some weekly immunoreactive perikarya were seen
(Fig. 5C). FtMt immunoreactivity was also observed inthe neuronal cytoplasm of the PPT (Fig. 5D).
Moderately intense staining of fusiform immunoreactive
neurons was seen in the PN (Fig. 5D).
Mildly stained FtMt-immunoreactive perikarya were
observed in the Mo5 (Fig. 5E). Several FtMt-positive
neurons were detected in the Me5, with intense and
punctate staining (Fig. 5F). In addition, typical
mitochondrial staining was detected in the LC (Fig. 5F).
Fig. 5. FtMt immunoreactivity in the pons of cynomolgus monkeys. (A–F) FtMt-immunoreactive neurons in the pons. Higher magniﬁcation images
of FtMt immunoreactivity are shown in the boxed areas. Arrowheads indicate immunoreactivity in the cytoplasm and neuronal processes. (A) Lateral
vestibular nucleus (LVe) and abducens nucleus (VI). (B) Median raphe nucleus (MR) and nucleus reticularis tegmenti pontis (RTP). (C) Ventral
raphe nucleus (VR). (D) Pontine nuclei (PN) and pedunculopontine tegmental nucleus (PPT). (E) Motor trigeminal nucleus (Mo5). (F) Locus
coeruleus (LC) and mesencephalic nucleus of the trigeminal nerve (Me5). Scale bars = 500 lm (A–D), 100 lm (E, F).
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Some regions in the medulla oblongata exhibited FtMt
immunoreactivity, including MCU, GR, LCU, MLF, RO,
Sp5, AMB, SSp, LR, MVe, SOL, DMNV, XII, and IO
(arrowheads in Figs. 6 and 7A–D).
Highly immunoreactive and variably shaped neurons
were observed in the MCU (Fig. 6A). In the GR,
mild punctate FtMt immunoreaction was detected
in neurons (Fig. 6B). Strong FtMt-immunoreactive
neurons were seen in the LCU (Fig. 6C). Moderately
FtMt-immunoreactive neurons and neuronal short
processes were visible in the MLF (Fig. 6D). Mildly
oval-shaped stained neurons were found in the RO
(Fig. 6D). Moderate intensity, punctate FtMt-stained
neurons were observed in the Sp5 (Fig. 6E). In the
AMB, clusters of strongly FtMt-immunoreactive neurons
were detected (Fig. 6E). In the SSp, intense fusiform
FtMt immunoreactivity appeared in elongated neuroncell body and their processes (Fig. 6E). In the LR,
FtMt-immunoreactive perikarya were also observed
(Fig. 6E). A large number of uniformly distributed FtMt
staining was seen throughout the IO (Figs. 6E and 7D).
In the MVe, variably shaped FtMt-immunoreactive
neurons were observed (Fig. 7A). Abundant areas of
weak, punctate FtMt immunoreactivity was observed in
the SOL (Fig. 7B). In the DMNV and XII, obvious
punctate perinuclear staining was detected in FtMt-
immunoreactive neurons (Fig. 7C).Distribution of FtMt-immunoreactive structures in the
cerebellum
We also observed intense FtMt immunoreactivity in the
cerebellum (Fig. 7E). A large number of closely packed
areas of staining were detected in the granule layer (G)
of the cerebellar gray matter, and moderately intense
Fig. 6. FtMt immunoreactivity in the medulla oblongata of cynomolgus monkeys. (A–E) Immunoreactive neurons in the speciﬁc region of medulla
oblongata. Boxed areas show higher magniﬁcation images of FtMt immunoreactivity. Arrowheads indicate punctate immunoreactivity in the
cytoplasm and neuronal processes. (A) Medial cuneate nucleus (MCU). (B) Gracile nucleus (GR). (C) Lateral cuneate nucleus (LCU). (D) Medial
longitudinal bundle (MLB) and raphe obscurus nucleus (RO). (E) Ambiguous nucleus (AMB), inferior olivary nucleus (IO), lateral reticular nucleus
(LR), spinal trigeminal nucleus (Sp5), and supraspinal nucleus (SSp). Scale bars = 500 lm (A, D, E), 200 lm (B, C).
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Fig. 7. FtMt immunoreactivity in the medulla oblongata and cerebellum of cynomolgus monkeys. (A–D) FtMt-immunoreactive neurons in the
medulla oblongata. Boxed areas are higher magniﬁcation images of FtMt immunoreactivity. Arrowheads indicate punctate immunoreactivity in the
cytoplasm and neuronal processes. (A) Medial vestibular nucleus (MVe). (B) Solitary nucleus (SOL). (C) Dorsal motor nucleus of the vagus (DMNV)
and hypoglossal nucleus (XII). (D) Inferior olivary nucleus (IO), (E–G) FtMt staining in the cerebellum. (F, G) Higher magniﬁcation image showing a
large number of closely packed areas of FtMt immunoreactivity in granule cells (G cells), along with immunoreactive cells in the molecular layer (M
layer). Strong staining was present in Purkinje cells (P, arrows). FtMt staining was also observed in deep cerebellar nuclei (arrowheads). Scale
bars = 500 lm (A, D, E), 200 lm (B, C), 100 lm (F, G).
M. Yang et al. / Neuroscience 328 (2016) 92–106 101staining was visible in the molecular layer (M). Distinct
FtMt was sparse but consistently observed in Purkinje
cells (P) (Fig. 7E, F). In addition, FtMt-immunoreactiveneurons were equally distributed in the medial,
interposed, and lateral nucleus of the cerebellum
(Fig. 7E, F).
Table 2. Percentage of neurons double-stained for tyrosine hydroxy-
lase (TH) and mitochondrial ferritin (FtMt) relative to the total
populations of TH-positive neurons (upper row) and FtMt-positive
neurons (lower row) in the brainstems of cynomolgus monkeys
Region VTA
(%)
SNc
(%)
LC
(%)
Percentage of double-positive neurons
among total TH-positive neurons
56.89 69.18 63.64
Percentage of double-positive neurons
among total FtMt-positive neurons
71.73 66.40 75.66
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the monkey brainstem
To test the possibility that catecholaminergic neurons
express FtMt, double immunoﬂuorescence
histochemistry was employed. We subjected monkey
brainstem samples to double immunostaining for FtMt
and TH. Our results revealed relatively strong
co-localization of FtMt- and TH-positive neurons (white
arrows) in the VTA (Fig. 8A–C), SNc (Fig. 8D–F), and
LC (Fig. 8G–I). Co-localization occurred mainly in the
perikarya. Particularly strong FtMt staining was
observed in the Me5 (Fig. 8I), consistent with the
previous immunohistochemical result (Fig. 5F).
The percentage of co-FtMt and TH immunoreactivity
co-localization is shown in Table 2. A high percentage of
neurons were doubly stained relative to the number of
TH-positive neurons in the VTA (56.89%), SN
(69.18%), and LC (63.64%), and the percentages of
double-positive neurons to total FtMt-positive neurons
were 71.73% in VTA, 66.40% in SNc, and 75.66%
in LC.Fig. 8. Double immunoﬂuorescent staining for FtMt (green) and TH (red), sh
ventral tegmental area (VTA) (A–C), substantia nigra (SN) (D–F), and locus
exhibited co-localization of FtMt and TH immunoreactivity. (I) Nearly all
High-intensity FtMt staining was observed in the Me5 (white arrowheads
bars = 50 lm (A–F), 25 lm(G–I).DISCUSSION
Characterization of the FtMt antibody
In the present study, when we using Western blotting test
the expression of FtMt in the monkey brainstem, the FtMt
antibody detected a single band only in crude protein and
mitochondrial fraction extracted from monkey brainstem
with an approximate molecular weight of 22 kDa. This
band showed no decrease when the FtMt antibody wasowing co-localization of FtMt-positive and TH-positive neurons in the
coeruleus (LC) (G–I). (C, F) Numerous neurons in the VTA and SN
FtMt-positive neurons in the LC were also TH immunoreactive.
). White arrows indicate double-positive neurons (C, F, I). Scale
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was not observed when the FtMt antibody was omitted or
pre-absorbed with antigenic peptide (CTLGNENKQN).
Meanwhile, this band was observed in diﬀerent
molecular weight with FTH, thus the antibody does not
recognize monkey H-ferritin. Moreover, in another study
conducted by our group, this FtMt antibody was not
found to cross-react with human FTH in HEK293 cells
(Yang et al., 2015). In addition, the immunohistochemical
study using the antibody showed that FtMt-positive neu-
rons were observed in speciﬁc brain regions, and they
were abolished by the antibody which was pre-absorbed
with FtMt peptide. Furthermore, double immunoﬂuores-
cent histochemistry for FtMt and COX4 conﬁrmed the
mitochondrial localization of FtMt. These results indicate
that this antibody recognized FtMt speciﬁcally in the mon-
key brain.
Distribution of FtMt in the monkey brainstem
This is the ﬁrst study to map FtMt protein distribution in the
brainstem. We demonstrated that FtMt immunoreactivity
was observed preferentially in neuronal cells of the
brainstem, where it was observed in the mitochondria
and cytoplasm of somata and neuronal processes. The
neuronal localization of FtMt is in good agreement with
previous reports (Snyder et al., 2010; Wang et al.,
2011), even if some oligodendrocytes were reported to
be also positive for FtMt. In this study, except
TH-double-labeling, we did not perform further double-
labeling analysis to distinguish other cell types. We
suspect that FtMt expression in glial cells is either absent
or very low in normal physiological conditions, but that
cannot rule out the possibility of an increase under patho-
logical conditions. Our previous study showed that FtMt
mRNA was mainly localized in neurons of normal human
brain, but some glial cells expressing FtMt mRNA were
detected in the brains of AD patients (Wang et al., 2011).
Since FtMt is an iron storage protein, one may ask
whether its distribution is aﬀected by the iron status.
Indeed, there is accumulating evidence demonstrating
that iron is homogenously distributed in the normal adult
human brain, with higher levels in the midbrain (i.e., SN)
and cerebellum than in the pons and medulla (House
et al., 2012; Ramos et al., 2014; Zucca et al., 2015).
For example, FtMt immunoreactivity in the iron-rich SN
did not appear to be more robust than in other nuclei of
the midbrain, such as the III. These ﬁndings suggest that
distribution of FtMt is not aﬀected by the iron content in
the brainstem. This is in accord with a previous report in
which FtMt expression was indicated to be iron-
independent because of the lacking IREs (Levi et al.,
2001). A previous study reported that FtMt expression
may be inﬂuenced by the mitochondrial density, but not
by iron content (Snyder et al., 2009). Our results provide
evidence for the hypothesis, as the diﬀerences in the
intensity and form of FtMt immunostaining appear to be
consistent with mitochondrial density and neuronal activity.
Interestingly, a terminal enzyme of the mitochondrial
electron transport chain, COX4, is considered an
indicator of the metabolic abilities and functional activity
of neurons (Wong-Riley, 1989). Some studies observedpositive staining for Cox4 and ubiquitous mitochondrial
creatine kinase, an important enzyme for neuronal energy
metabolism, in the human brainstem. The stained neu-
rons appeared in the DR, IC, III, IV, Me5, PAG, SC,
SNc, and RN of the midbrain; LC, LVe, MR, Mo5, PN,
Sp5, VI, and VII of the pons; and AMB, CU, DMNV, GR,
IO, LR, MLF, MVe, SOL, and XII of the medulla (Liu
and Wong-Riley, 2003, 2005; Lowe et al., 2013). Overall,
our results regarding the distribution of FtMt-positive
neurons in the brainstem were very similar to the
mitochondrial distributions described in earlier reports,
particularly in terms of the intensity and pattern of
staining. In addition, FtMt-staining in the M, G, and P of
the cerebellum was also consistent with mitochondrial
distribution (Nie and Wong-Riley, 1996).
The main role of the mitochondria is to supply cellular
energy; accordingly, mitochondrial density represents the
energy consumption and demand of a cell, as well as its
activity level (McBride et al., 2006). Mitochondrial density
is among the main determinants of the metabolic rate, as
this factor indicates the maximum rate of energy conver-
sion from stored material (Pathi et al., 2013). To satisfy
their bioenergetic needs, neurons require high level of
mitochondrial oxidative phosphorylation, which is a major
cellular source of ROS. This may imply the ROS content
is proportional to the mitochondrial density in neurons
(Chance et al., 1979; Nicholls, 2008; Sanchez-Padilla
et al., 2014). However, some pathological conditions
can induce more ROS production than cellular antioxidant
capacity, such as in the LC and SNc of PD patients
(Dickson, 2012; Hauser and Hastings, 2013). Our previ-
ous in vitro study indicated that the increased mRNA
and protein levels expression of FtMt may be induced
by ROS and Amyloid beta (Wang et al., 2011). These
suggest FtMt is not constitutively expressed, but its
expression might change in pathologic conditions.
Indeed, increased FtMt expression was observed in the
temporal cortexes of patients, compared with normal indi-
viduals, and was also observed in the SN of PD or RLS
patients (Nie et al., 2005; Snyder et al., 2009; Wang
et al., 2011). Taken together, these ﬁndings suggest that
FtMt expression is inﬂuenced by either mitochondrial den-
sity and functional activity of neurons. As the present
study is restricted to 5–11-year-old normal disease-free
M. fascicularis, we did not see direct evidence about this
alteration or the expression of FtMt in diﬀerent age monkeys.
Further studies are needed to establish the age-related
and pathological conditions induced expression of FtMt.
FtMt in neurodegenerative diseases
Many studies have implicated FtMt in some
neurodegenerative diseases such as AD, PD, and RLS.
Parkinsonism is a very common neurodegenerative
disorder characterized by prominent bradykinesia and
extrapyramidal signs. A key feature of PD is the build-up
of a-synuclein in Lewy bodies (Dickson, 2012). Free iron
is toxic, causing oxidation and cell damage, and uncon-
trolled iron levels tend to rise with aging (Connor et al.,
1990; Zecca et al., 2004). Also, excess iron tends to be
associated with neurodegenerative diseases, particularly
AD and PD (Zecca et al., 2004; Kell, 2010). Recent
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layers of the cerebral cortex and in the cerebellum, hip-
pocampus, striatum, and SN (Shi et al., 2010; Snyder
et al., 2010). Although FtMt has been thought to prevent
cell death induced by ROS and neurotoxic proteins in
patients with neurodegenerative disease by maintaining
iron homeostasis (Nie et al., 2005; Snyder et al., 2009;
Wang et al., 2011), there is little information about FtMt
expression in brainstem regions in association with these
diseases.
In the present study, FtMt-immunoreactive neurons
were recognized in the extrapyramidal system (SC, IC,
RN, PN, LR, LVe, MVe, DR, and MR), some motor
nuclei (AMB, DMNV, and XII) and some regions contain
catecholaminergic neurons (SN, LC and VTA). The
staining of FtMt appeared similar in these regions, with
typical punctate mitochondrial staining. Evidence
suggests that iron deposition increases with normal
aging, is most strongly present in structures of the
extrapyramidal system, and might be a cause to
functional decline (Bartzokis et al., 2007). A new study
shows that a-synuclein overexpression contributes to iron
accumulation in neurons (Ortega et al., 2016). Studies
have shown that Lewy bodies, which are composed of
the protein a-synuclein, are most prevalent in the SN,
VTA, PPT, AMB, DMNV, XII, SOL, LC, raphe nuclei, peri-
aqueductal gray matter, and reticular formation in PD
patients (Kingsbury et al., 2010; Kokubo et al., 2012;
Seidel et al., 2015). In another study by our group, FtMt
modulates a-synuclein expression via iron regulation in
physiological conditions (submitted paper).
In the present study, FtMt immunoreactivity was
observed in the sensory trigeminal nerve nuclei (MeV,
Sp5, and V) and dorsal column nuclei (GR, LCU, and
MCU). Friedreich’s ataxia (FRDA) is another neuropathy
associated with mitochondrial iron control: when the
iron-controlling mitochondrial protein called frataxin is
lacking, the resulting uncontrolled iron causes neural
damage. Among the eﬀects is a severe loss of
secondary sensory neurons, including the spinal and
principal trigeminal nuclei and, in particular, the
mesencephalic trigeminal nucleus in the brainstem
(Jitpimolmard et al., 1993), and neuronal atrophy in the
GR and CU has been observed in FRDA (Koeppen and
Mazurkiewicz, 2013). Being another mitochondrial
iron-holding protein, FtMt may act to limit the damage in
FRDA by modulating mitochondrial iron availability, and
hence reducing oxidative damage (Zanella et al., 2008;
Campanella et al., 2009).
In general, the distribution of FtMt immunoreactivity
seen in the present study provides support for previous
studies and suggests that FtMt may be important in
neurodegenerative diseases, especially Parkinsonism.
Exactly what FtMt does in the brainstem (and
elsewhere) in normal and abnormal physiology has yet
to be clariﬁed.
FtMt in the catecholaminergic neurons
In the current study, we observed FtMt immunoreactivity
in neurons of the VTA, SN, and LC which are the
regions contains catecholaminergic neurons. Doubleimmunoﬂuorescent staining for FtMt and TH conﬁrmed
that the percentages of double-positive neurons to total
TH-positive neurons were 56.89% in VTA, 69.18% in
SNc and 63.64% in LC.
Interestingly, several studies have reported possible
involvements of FtMt in midbrain dopaminergic neurons
aﬀected by neurological disorders such as PD (Shi
et al., 2010) and RLS (Snyder et al., 2009). PD is well
known as the loss of melanin-containing dopaminergic
neurons in the SNc and to a lesser extent in the noradren-
ergic neurons in the LC. The neurons in these two regions
may be preferentially destroyed by oxidative damage
(Halliwell, 2006; Dickson, 2012). A study reported that
cumulating oxidative stress may lead to a cellular energy
shortage resulting from mitochondrial dysfunction
(Nicholls, 2008). FtMt, by controlling iron in mitochondria,
protects against oxidative stress to neurons through the
Fenton reaction (Yang et al., 2013).
Dopaminergic neurons of the midbrain include two
important sets of projecting cells: the ‘‘A9” neurons
projecting from the SN and the ‘‘A10” cells from the
VTA (Grison et al., 2014). In PD, selective degeneration
occurs in A9 neurons but not A10 cells. Normally,
dopaminergic neurons in the SNc are signiﬁcantly more
sensitive to oxidative stress than are those in the VTA
(Horowitz et al., 2011). However, abnormal A10 cell func-
tion has been linked to addiction, attention deﬁcit, and
schizophrenia (Grison et al., 2014). Interestingly, our pre-
vious study indicated that oxidative stress could increase
the expression of both FtMt mRNA and protein (Wang
et al., 2011). A previous study reported that some sub-
populations of LC neurons are very sensitive to oxidative
stress (de Oliveira et al., 2012). Although there is no direct
evidence, it may be conjectured that more FtMt might be
expressed in such LC neurons. Together our observa-
tions may imply the diﬀerent expression of FtMt in the
TH-positive neurons in the VTA, LC and SN related to
regional diﬀerences in sensitivity to oxidative stress.
These ﬁndings suggest FtMt may be important in cate-
cholaminergic neurons.
CONCLUSION
In the present study, we characterized a new human FtMt
antibody, and with it created the ﬁrst map of FtMt
immunoreactivity in a monkey brainstem. This showed
the widespread distribution of FtMt in various brainstem
regions and co-localization with catecholaminergic
neurons in the LC, SN, and VTA, suggesting that FtMt
plays a signiﬁcant role in catecholamine neurons and
more importantly, it could be involved in
neurodegenerative diseases such as Parkinsonism and
ataxia. The map of FtMt immunoreactivity should give
fundamental data to understand roles of FtMt in
physiological and pathological brain functions.
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